News provided by Eli Lilly and Company Dec 11, 2025, 06:45 ET In TRIUMPH-4, participants with obesity and knee osteoarthritis taking retatrutide 12 mg lost an average of 28.7% of their body weight at 68 weeks Retatrutide reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function, with more than 1 out of 8 retatrutide-treated patients completely free from knee pain at the end of the trial Seven additional Phase 3 trials evaluating the investigational once-weekly treatment in obesity and type 2 diabetes are expected to complete in 2026 INDIANAPOLIS, Dec
For example, people with specific gastrointestinal disorders might be more susceptible to the digestive side effects of the medication
9 Administration UFaD
Siempre que el paciente se mantenga en un peso estable, los resultados se mantienen
Come per qualsiasi integratore, tuttavia, possono comparire effetti indesiderati in soggetti particolarmente sensibili
Diethylpropion and Phendimetrazine These older appetite suppressants may be considered for selected patients when medically appropriate